Our History

Establishment of Pharmathen by the pharmacist Nikolaos Katsos

Commencement of manufacturing activities

First in-house development

Leadership passes to Vassilios Katsos and Nelly Katsou

Strategic refocusing of business activities in order to target the international market

Launch of Pharmathen’s first product in the E.U. (Fluconazole)

Inauguration of API research facility in Thessaloniki — a step towards vertical integration

Acquisition of a research facility for API synthesis in India

Global presence extends to 65 countries

Commencement of operations at our new manufacturing unit in Sapes, North Greece

Initiation of new R&D activities focused on specialty products

The Group exceeds the landmark of €150 million in turnover

Initiation of new commercial activities for pharmacies in Greece, representing renowned international brands

First product launch and commencement of business activities in the United States

First Greek Company to be financed by European Investment Bank

Front runners in Long Acting Injectables (LAI) technologies and Preservative Free Ophthalmics

Acquisition of a majority stake of shares of the Group by the investment group BC Partners

Incorporation of the Dutch parent company, Pharmathen Global BV

Successful completion of our first Long-Acting Injectable development

Successful completion of our first inspection by U.S. Food & Drug Administration

Expansion in Long-Acting Injectable facilities and commencement of construction of two more LAI plants

More than 200 new employees experienced our unique culture

Pharmathen celebrates 50 years of improving the quality of life of millions of people around the world

Official launch of a new Long-Acting Injectables Unit at Sapes, Rodopi

Obtaining the first marketing authorization for Long-Acting Injectables in Europe

Receiving a second marketing authorization for Long-Acting Injectables in Europe

USFDA approval for two products in the U.S.A.

More than 250 positions filled amid the COVID-19 pandemic

Pharmathen’s ownership passes to the investment firm Partners Group

FDA approves the first generic microsphere LAIs (naltrexone, risperidone, octreotide)

Acquisition of CBL Patras